An interventional study of Biofeedback-Based Pelvic Floor Rehabilitation and Transcutaneous Auricular Vagus Nerve Stimulation (Active taVNS) in Dyssynergic Defecation, sponsored by Istanbul Bilgi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Istanbul Bilgi University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Constipation with a site in Turkey — 16 open to participants now, 21 under way, none of them phase 3. Constipation · Turkey.
Among the 72 studies in Constipation with a site in Turkey, this one is the 48th largest by enrollment of the 57 interventional ones that give a count, is one of 12 that started in 2026, is one of 56 with no phase, and was the 72nd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →16 of the 72 studies in Constipation with a site in Turkey are open now. Recruiting first, the newest first:
Cumhuriyet University · Sites in Turkey
Ages 18+ · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–45 · Healthy volunteers
HAMİYET KIZIL · Sites in Turkey
Ages 18+
Kocaeli University · Sites in Turkey
Ages 18–70
Lokman Hekim University · Sites in Turkey
Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 12 started in 2026.
This study's enrollment of 32 is below the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 54 across the 57 interventional studies, 128 across the 15 observational. Of the 46 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 72 has an industry lead sponsor. The 10 most frequent:
Istanbul Bilgi University is the lead sponsor of 53 studies on the registry; 3 are open to participants now.
Istanbul Bilgi University has 1 study filed under Constipation — fewer than ten, so there is no comparison to draw.
5 of the studies in Constipation with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07732894Biruni UniversityAerobic Exercise and Guided Imagery in Low Anterior Resection Syndrome | 2026-12-30 |
| NCT07886125HAMİYET KIZILEffect of Abdominal Massage Training Provided to Caregivers on Constipation Management | 2027-03 |
| NCT07870915Saglik Bilimleri UniversitesiRelationship Between Interoception and Postural Control in Constipation-Predominant Irritable Bowel Syndrome | 2027-03-31 |
| NCT07668765Gazi UniversityGLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | 2027-04 |
| NCT07895316Cumhuriyet UniversityEffect of a Constipation Prevention Checklist in Hip Surgery Patients | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Constipation with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biofeedback-based pelvic floor rehabilitation is an established treatment approach for dyssynergic defecation (DD), aiming to restore appropriate muscle coordination during defecation. However, the potential role of autonomic nervous system regulation and stress responses in gastrointestinal function has encouraged the investigation of additional therapeutic approaches.
This randomized, sham-controlled clinical trial aims to evaluate the additional effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with biofeedback-based pelvic floor rehabilitation, compared with sham stimulation combined with the same rehabilitation program, on constipation symptoms, defecation function, pelvic floor muscle activity, autonomic regulation, psychological symptoms, and quality of life in individuals with dyssynergic defecation.
Dyssynergic defecation (DD) is a functional defecation disorder associated with chronic constipation and characterized by impaired coordination of the pelvic floor muscles and anal sphincter during defecation. Biofeedback-based pelvic floor rehabilitation is recommended as a first-line treatment approach for dyssynergic defecation. However, the relationship between autonomic nervous system regulation, psychological factors, and gastrointestinal function has encouraged the investigation of additional therapeutic interventions. Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that may influence autonomic regulation.
This prospective, randomized, sham-controlled clinical trial enrolled 32 participants aged 18-65 years diagnosed with dyssynergic defecation in general surgery and gastroenterology clinics. Participants were allocated into two groups using computer-generated block randomization: an active taVNS group (n=16) and a sham stimulation group (n=16).
Both groups received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. In the intervention group, participants additionally received 30 minutes of transcutaneous auricular vagus nerve stimulation during each rehabilitation session. In the sham group, electrodes were placed at the same anatomical locations, but therapeutic electrical stimulation was not delivered.
Assessments were conducted before and after the treatment period. Constipation severity was evaluated using the Constipation Severity Instrument (CSI), colorectal symptoms using the Colorectal-Anal Distress Inventory-8 (CRADI-8), constipation-related quality of life using the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL), and psychological symptoms using the Hospital Anxiety and Depression Scale (HADS). Bowel habits were recorded using the Bristol Stool Form Scale and a defecation diary. Pelvic floor muscle activity was assessed using a surface electromyography (EMG) biofeedback system, focusing on work average and rest average parameters. Cardiac autonomic regulation was assessed through heart rate variability (HRV) analysis, including RMSSD, SDNN, pNN50, LF Power, HF Power, and the LF/HF ratio.
The study aimed to evaluate the additional effects of active taVNS combined with biofeedback-based pelvic floor rehabilitation compared with sham stimulation on constipation severity, colorectal symptoms, bowel habits, pelvic floor muscle activity, constipation-related quality of life, psychological symptoms, and cardiac autonomic regulation in individuals with dyssynergic defecation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18-65 years. Diagnosis of dyssynergic defecation (DD). Ability to read and understand the study procedures. Provision of written to participate in the study.
Exclusion Criteria:
Pregnancy or breastfeeding. Severe neurological disorders (e.g., multiple sclerosis or Parkinson's disease).
Presence of a cardiac pacemaker or other implanted electronic device. Uncontrolled hypertension or cardiac disorders. Diagnosis of severe anxiety disorder or depression. Use of medications that affect balance. Structural or metabolic disorders that may cause chronic constipation (e.g., Hirschsprung's disease).
Presence of an acute ear infection or wound. Previous treatment with pelvic floor rehabilitation or transcutaneous auricular vagus nerve stimulation (taVNS).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. In addition, 30 minutes of active transcutaneous auricular vagus nerve stimulation (taVNS) was administered during each session.
Behavioral: Biofeedback-Based Pelvic Floor Rehabilitation · Device: Transcutaneous Auricular Vagus Nerve Stimulation (Active taVNS)
Participants in this group received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. Sham taVNS was administered for 30 minutes during each session, with electrodes placed at the same anatomical locations as in the active group, but without therapeutic electrical stimulation.
Behavioral: Biofeedback-Based Pelvic Floor Rehabilitation · Device: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Participants received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. The rehabilitation program included pelvic floor muscle awareness and relaxation training, coordination exercises between the abdominal and pelvic floor muscles, and education on appropriate defecation techniques. Surface electromyography (EMG) biofeedback was used to provide visual feedback on muscle activity and facilitate the learning of appropriate contraction and relaxation patterns. The intervention aimed to reduce inappropriate pelvic floor muscle contraction during defecation, improve muscle coordination, and promote effective bowel emptying.
Participants in the intervention group received active transcutaneous auricular vagus nerve stimulation (taVNS) in addition to biofeedback-based pelvic floor rehabilitation. Electrical stimulation was delivered through electrodes placed on the auricular region to target the auricular branch of the vagus nerve. Stimulation was administered for 30 minutes during each of the 16 rehabilitation sessions over a two-month period. The intervention aimed to modulate autonomic nervous system activity and investigate its potential additional effects on constipation symptoms, defecation function, psychological symptoms, and heart rate variability (HRV).
Participants in the sham group received biofeedback-based pelvic floor rehabilitation combined with sham transcutaneous auricular vagus nerve stimulation. Electrodes were placed at the same anatomical locations as in the active taVNS group, and the procedure was conducted for 30 minutes during each of the 16 rehabilitation sessions over a two-month period. However, therapeutic electrical stimulation was not delivered. The sham procedure was designed to be similar to the active intervention in appearance and duration to maintain participant blinding and allow evaluation of the additional effects of active taVNS.
Change in Constipation Severity Instrument (CSI) Total Score
Constipation severity was assessed using the 16-item Constipation Severity Instrument (CSI), comprising three subscales: obstructive defecation (0-28 points), colonic inertia (0-29 points), and pain (0-16 points). The total score ranges from 0 to 73, with higher scores indicating greater constipation severity. Changes in total CSI scores from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Colorectal-Anal Distress Inventory-8 (CRADI-8) Score
Colorectal and anal symptom distress was assessed using the eight-item Colorectal-Anal Distress Inventory (CRADI-8), a subscale of the Pelvic Floor Distress Inventory-20 (PFDI-20). Scores range from 0 to 100, with higher scores indicating greater symptom distress. Changes in scores from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Patient Assessment of Constipation Quality of Life (PAC-QOL) Score
Constipation-related quality of life was assessed using the 28-item Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire, comprising four domains: worries and concerns, physical discomfort, psychosocial discomfort, and satisfaction. Higher scores indicate a greater negative impact of constipation on quality of life. Changes from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score
Anxiety symptoms were assessed using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21, with higher scores indicating greater anxiety symptoms. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score
Depressive symptoms were assessed using the seven-item depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scores range from 0 to 21, with higher scores indicating greater depressive symptoms. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Pelvic Floor Muscle EMG Work Average (µV)
Pelvic floor muscle electrical activity during contraction was assessed using surface electromyography (EMG) with the NeuroTrac MyoPlus2 Pro device. Work Average was recorded in microvolts (µV) during repeated five-second contractions. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Pelvic Floor Muscle EMG Rest Average (µV)
Pelvic floor muscle electrical activity during relaxation was assessed using surface electromyography (EMG) with the NeuroTrac MyoPlus2 Pro device. Rest Average was recorded in microvolts (µV) during repeated five-second relaxation periods. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Heart Rate Variability - RMSSD (ms)
Heart rate variability was assessed using the Polar H10 chest strap and Elite HRV application. RMSSD, the root mean square of successive differences between normal-to-normal RR intervals, was measured in milliseconds (ms). Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Heart Rate Variability - pNN50 (%)
Heart rate variability was assessed using the Polar H10 chest strap and Elite HRV application. pNN50 represents the percentage of successive normal-to-normal RR intervals differing by more than 50 milliseconds. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Heart Rate Variability - LF Power
Low-frequency (LF) power was assessed through frequency-domain heart rate variability analysis using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Heart Rate Variability - HF Power
High-frequency (HF) power was assessed through frequency-domain heart rate variability analysis using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Heart Rate Variability - LF/HF Ratio
The ratio of low-frequency to high-frequency power (LF/HF) was calculated from heart rate variability measurements obtained using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.
Time frame: Baseline and 2 months (post-intervention)
Change in Weekly Bowel Movement Frequency
Weekly bowel movement frequency was assessed using a defecation diary. The number of bowel movements per week was recorded at baseline and after the two-month intervention period. Changes in weekly bowel movement frequency were compared between the active taVNS and sham taVNS groups. Higher values indicate more frequent bowel movements.
Time frame: Baseline and 2 months (post-intervention)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Oct 2026, 7 months.
Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 7 months is below that.
Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Bilgi University